CompletedNot Applicable

Effects of Aerobic Versus Resistance Training on Bone Metabolism in Stage 3-4 Chronic Kidney Disease

Egypt60 participantsStarted 2025-01-01

Plain-language summary

This randomized controlled trial investigates the comparative effects of aerobic versus resistance training on bone mineral density (BMD) and bone metabolism markers in patients with stage 3 or 4 chronic kidney disease (CKD). The primary aim is to evaluate the impact of two distinct exercise modalities on serum osteoprotegerin (OPG), receptor activator of nuclear factor kappa-B ligand (RANKL), and the OPG/RANKL ratio, as well as densitometric changes at key skeletal sites.

Who can participate

Age range30 Years – 50 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Adults aged 30 to 50 years * Diagnosed with stage 3 or 4 chronic kidney disease (non-dialysis dependent) * BMI between 20 and 24 kg/m² * Not currently taking medications that affect bone density (e.g., corticosteroids, bisphosphonates) * Non-smokers and abstinent from alcohol * Not receiving hormone replacement therapy * Willing and able to participate in supervised exercise sessions for 6 months Exclusion Criteria: * Diagnosis of type 1 diabetes mellitus * Uncontrolled hypertension * History of cardiovascular, musculoskeletal, endocrine, or metabolic bone disease * Pregnant or planning pregnancy during the study period * Participation in a structured exercise program within the last 3 months * Contraindications to exercise as determined by medical evaluation * Use of investigational drugs or enrollment in another clinical trial during the study period

What they're measuring

Change in Serum Osteoprotegerin (OPG) and RANKL Concentrations

Timeframe: Baseline to 6 months post-intervention

Change in Bone Mineral Density (BMD)

Timeframe: Baseline to 6 months post-intervention

Change in OPG/RANKL Ratio

Timeframe: To assess the regulatory balance of bone remodeling. A higher OPG/RANKL ratio reflects reduced osteoclastic activity and improved bone metabolic status.

Trial details

NCT IDNCT07133256

SponsorSinai University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-07-01

View on ClinicalTrials.gov More Osteopenia trials

Plain-language summary

Who can participate

Age range30 Years – 50 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

What they're measuring

Change in Serum Osteoprotegerin (OPG) and RANKL Concentrations

Timeframe: Baseline to 6 months post-intervention

Change in Bone Mineral Density (BMD)

Timeframe: Baseline to 6 months post-intervention

Change in OPG/RANKL Ratio

Timeframe: To assess the regulatory balance of bone remodeling. A higher OPG/RANKL ratio reflects reduced osteoclastic activity and improved bone metabolic status.